Population-level impact of Pneumococcal Conjugate Vaccines in older adults: Portuguese Report

IMOVE+ WP3: Pneumococcal vaccinesOverall objective: To estimate the population-level impact of pneumococcal conjugate vaccination on invasive pneumococcal disease (IPD), all-cause pneumonia (ACP) and pneumococcal pneumonia (PP) burden among adults 65 years of age and older. The impact measures we aimed to estimate were: The indirect effect of PCV7 given to children on IPD, ACP and PP burden among adults aged 65 years and more; The indirect effect of PCV13 (additional six serotypes) given to children on IPD, ACP and PP burden among adults aged 65 years and more. Specific objectives: To estimate the reduction of IPD, ACP and PP intra-hospital mortality among adults ≥65 years of age. Initially, in the Scientific Protocol, the reduction of intensive care unit (ICU) admission rate among adults aged 65 years or more hospitalized with IPD, ACP and PP associated with PCV7 and PCV13 introduction was considered. Nevertheless, given the variability of codes used between hospitals to identify ICU admissions, was not possible to achieve this objective. In addition, given the low number of annual hospitalizations due to pneumococcal sepsis and pneumococcal meningitis among adults aged 65 years and more the reduction of IPD hospitalization rate estimates by clinical presentation was not possible to perform.IMOVE+ (under grant agreement No 634446)N/